Another study revealed that compared with ER-/PR-/HER2+ breast cancers, ER+/PR+/HER2+ breast cancers exhibited different driving events, including lower TP53 mutation rate, lower ERBB2 amplification rate, and higher CCND1 amplification rate (7). This evidence concerns the gene ERBB2 and breast cancer.